{"altmetric_id":4693175,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Kevan Herold, Yale University"],"first_seen_on":"2015-10-28T15:13:17+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1268704772,"links":["http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00378508"],"nct_id":"NCT00378508","pubdate":"2006-09-18T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes","type":"clinical_trial_study_record"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":4433590,"mean":4.8085724060488,"rank":983259,"this_scored_higher_than_pct":64,"this_scored_higher_than":2879567,"rank_type":"exact","sample_size":4433590,"percentile":64},"similar_age_3m":{"total_number_of_other_articles":76366,"mean":5.3816429254239,"rank":13844,"this_scored_higher_than_pct":81,"this_scored_higher_than":62036,"rank_type":"exact","sample_size":76366,"percentile":81},"this_journal":{"total_number_of_other_articles":7043,"mean":2.8192053393922,"rank":1801,"this_scored_higher_than_pct":89,"this_scored_higher_than":6273,"rank_type":"exact","sample_size":7043,"percentile":89},"similar_age_this_journal_3m":{"total_number_of_other_articles":236,"mean":1.7942553191489,"rank":22,"this_scored_higher_than_pct":88,"this_scored_higher_than":208,"rank_type":"exact","sample_size":236,"percentile":88}}},"demographics":[],"counts":{"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:9134442"],"posts_count":1}},"posts":{"wikipedia":[{"title":"Visilizumab","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=350125556#altmetric_citation_3","license":"public","citation_ids":[4693175],"posted_on":"2010-03-16T01:59:32+00:00","summary":"PDL BioPharma, Inc. canceled production of visilizumab following its Phase II\/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.","page_url":"http:\/\/en.wikipedia.org\/?curid=9134442","wiki_lang":"en","author":{"name":"Mindmatrix","url":"http:\/\/en.wikipedia.org\/wiki\/User:Mindmatrix"}}]}}